Interestingly, Stanciu and colleagues have established that SGLT2 inhibitors are capable of repressing mTOR, which seems to bring benefits to patients with Alzheimer’s disease (Stanciu et al. 2021). The gene discussed is MTOR; the disease is early-onset autosomal dominant Alzheimer disease.